Human atrial natrieuretic polypeptide protect against LV remodeling in patients with AMI -prospective randomized trial assessed by QGS-

Backgrounds:The aim of this study is to demonstrate HANP administration combined with acute revascularization prevent LV remodeling independent of myocardial salvage. Methods:Consecutive 44 patients with acute anteroseptal myocardial infarction were randomly assigned to either continuous infusion of HANP at a dose of 0.025 microgram/kg/min for 3 days, or control. Myocardial salvage, infarct size, and LV volume was assessed by 99mTc-tetrofosmin imaging. Results:No differences in patients backgrounds were observed. HANP suppressed LVEDVI increase in comparison with placebo (HANP:3.2 ± 16.8 control:16.0 ± 23.4 p < 0.05) with no difference in salvage index(HANP:55.6 ± 24.9% control:55.5 ± 34.1%). The relationship between the infarct size and delta-LVEDVI were shown in the figure.Conclusion:This study clearly demonstrate that HANP can suppress LV volume expansion despite no difference of infarct size.